Stay updated on DTX301 Clinical Trial in Late-Onset OTC Deficiency
Sign up to get notified when there's something new on the DTX301 Clinical Trial in Late-Onset OTC Deficiency page.

Latest updates to the DTX301 Clinical Trial in Late-Onset OTC Deficiency page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information about DTX301 for treating OTC deficiency and the addition of a new revision number. The name of the condition, Ornithine Transcarbamylase (OTC) Deficiency, remains, but the context surrounding the study has been largely deleted.SummaryDifference17%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to DTX301 Clinical Trial in Late-Onset OTC Deficiency
Enter your email address, and we'll notify you when there's something new on the DTX301 Clinical Trial in Late-Onset OTC Deficiency page.